Skip to main content
    O

    Orthofix Medical Inc (OFIX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $6.80
    -0.37 (-5.16%)

    Market Cap: $292.25M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Orthofix Medical Inc (OFIX) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Orthofix Medical (OFIX) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Orthofix Medical reported EPS of -$0.15, above the -$0.31 estimate. It beat the EPS estimate in each of the last 17 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    83%(33/40)
    Avg Surprise
    +78.98%
    Streak
    17 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.07
    Range-$0.12 - -$0.02
    4 analysts
    Revenue Consensus
    $216.03M
    Range$207.17M - $222.92M
    6 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.20
    Range-$0.20 - -$0.20
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.25+20.0%
    60d ago-$0.200.0%
    30d ago-$0.200.0%
    7d ago-$0.200.0%
    Current-$0.20
    Revenue Consensus
    $190.84M
    Range$188.14M - $193.38M
    3 analysts

    Next Report

    OFIX has an expected report date of Feb 22, 2027.

    OFIX Earnings Call

    The latest OFIX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, OFIX beat 33 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $207.86M, up 1.1% from $205.63M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.15-$0.31N/A+51.61%Beat-175.0%11 up, 0 downNov 9, 2026$207.86M
    Jun 30, 2026-$0.39-$0.46N/A+15.22%Beat-400.0%11 up, 0 downAug 5, 2026$210.93M
    Mar 31, 2026-$0.11-$0.29-$0.29 - -$0.29+62.07%BeatN/A10 up, 0 downMay 5, 2026$196.71M
    Dec 31, 2025$0.24-$0.22N/A+208.09%Beat+1444.2%21 up, 0 downFeb 24, 2026$219.91M
    Sep 30, 2025$0.20$0.12$0.12 - $0.12+66.67%Beat+185.7%10 up, 1 downNov 4, 2025$205.63M
    Jun 30, 2025$0.13$0.04$0.04 - $0.04+225.00%Beat+160.0%10 up, 0 downAug 5, 2025$203.12M
    Mar 31, 2025-$0.03-$0.27-$0.38 - -$0.17+88.89%Beat-127.3%30 up, 1 downMay 6, 2025$193.65M
    Dec 31, 2024$0.02-$0.05-$0.12 - $0.08+130.80%Beat-48.7%30 up, 2 downFeb 25, 2025$215.66M
    Sep 30, 2024$0.07-$0.15-$0.20 - -$0.11+146.67%Beat0.0%30 up, 0 downNov 7, 2024$196.61M
    Jun 30, 2024$0.05-$0.19-$0.23 - -$0.13+126.32%Beat+150.0%30 up, 0 downAug 6, 2024$198.62M
    Mar 31, 2024$0.11-$0.33-$0.35 - -$0.32+133.33%BeatN/A30 up, 0 downMay 7, 2024$188.61M
    Dec 31, 2023$0.03-$0.08-$0.49 - $0.22+137.50%Beat-84.2%40 up, 0 downMar 5, 2024$200.41M
    Sep 30, 2023$0.07-$0.21-$0.23 - -$0.18+133.33%Beat-46.2%40 up, 0 downNov 8, 2023$184.01M
    Jun 30, 2023$0.02-$0.47-$0.67 - -$0.17+104.26%Beat-75.0%30 up, 0 downAug 8, 2023$187.02M
    Mar 31, 2023-$0.10-$0.35-$0.83 - -$0.20+71.43%BeatN/A30 up, 1 downMay 9, 2023$175.20M
    Dec 31, 2022$0.19$0.10N/A+90.00%Beat-29.6%20 up, 0 downMar 6, 2023$122.23M
    Sep 30, 2022$0.13$0.12$0.02 - $0.18+8.33%Beat+30.0%31 up, 0 downNov 3, 2022$114.00M
    Jun 30, 2022$0.08$0.10N/A-20.00%Miss-75.0%N/A1 up, 1 downAug 5, 2022$118.07M
    Mar 31, 2022-$0.10$0.09-$0.03 - $0.18-211.11%Miss-158.8%30 up, 0 downMay 6, 2022$106.42M
    Dec 31, 2021$0.27$0.13$0.13 - $0.13+107.69%Beat-38.6%2N/AFeb 25, 2022$125.06M
    Sep 30, 2021$0.10$0.09$0.06 - $0.19+11.11%Beat-67.7%3N/ANov 5, 2021$112.43M
    Jun 30, 2021$0.32$0.11$0.06 - $0.19+190.91%BeatN/A4N/AAug 6, 2021$121.39M
    Mar 31, 2021$0.17$0.02-$0.05 - $0.18+750.00%Beat+88.9%4N/AApr 30, 2021$105.59M
    Dec 31, 2020$0.44$0.19$0.14 - $0.27+131.58%Beat-13.7%4N/AFeb 26, 2021$117.62M
    Sep 30, 2020$0.31-$0.14-$1.27 - $0.07+321.43%Beat-24.4%5N/ANov 5, 2020$110.98M
    Jun 30, 2020-$0.59-$0.75-$1.74 - -$0.70+21.33%Beat-310.7%3N/AAug 6, 2020$73.14M
    Mar 31, 2020$0.09$0.06-$0.03 - $0.11+50.00%Beat-66.7%3N/AMay 8, 2020$104.82M
    Dec 31, 2019$0.51$0.58$0.51 - $0.61-12.07%Miss-7.3%4N/AFeb 24, 2020$121.49M
    Sep 30, 2019$0.41$0.51$0.50 - $0.52-19.61%Miss-4.7%4N/AOct 28, 2019$113.50M
    Jun 30, 2019$0.28$0.42$0.40 - $0.44-33.33%Miss-33.3%4N/AAug 5, 2019$115.85M
    Mar 31, 2019$0.27$0.36$0.34 - $0.40-25.00%Miss-30.8%5N/AMay 6, 2019$109.11M
    Dec 31, 2018$0.55$0.48$0.44 - $0.49+14.58%Beat+5.8%5N/AFeb 25, 2019$121.08M
    Sep 30, 2018$0.43$0.36$0.36 - $0.37+19.44%Beat+2.4%5N/AOct 29, 2018$111.71M
    Jun 30, 2018$0.42$0.36$0.35 - $0.37+16.67%Beat0.0%5N/AAug 6, 2018$111.55M
    Mar 31, 2018$0.39$0.35$0.32 - $0.40+11.43%Beat+44.4%4N/AApr 30, 2018$108.71M
    Dec 31, 2017$0.52$0.50$0.48 - $0.52+4.00%Beat+23.8%4N/AFeb 26, 2018$116.90M
    Sep 30, 2017$0.42$0.38$0.31 - $0.45+10.53%Beat+16.7%6N/AOct 30, 2017$105.25M
    Jun 30, 2017$0.42$0.37$0.32 - $0.42+13.51%Beat+2.4%6N/AAug 7, 2017$108.94M
    Mar 31, 2017$0.27$0.29N/A-6.90%Miss-3.6%N/AN/AMay 4, 2017$102.74M
    Dec 31, 2016$0.42$0.37N/A+13.51%Beat+50.0%N/AN/AFeb 27, 2017$108.54M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.54, up 119.2% from the year before. It was $1.47 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.54+119.2%
    Dec 31, 2024$0.25+1127.0%
    Dec 31, 2023$0.02-93.3%
    Dec 31, 2022$0.30-65.1%
    Dec 31, 2021$0.86+244.0%
    Dec 31, 2020$0.25-83.0%
    Dec 31, 2019$1.47-17.9%
    Dec 31, 2018$1.79+9.8%
    Dec 31, 2017$1.63+10.9%
    Dec 31, 2016$1.47N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,700 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,7288
    2026Q2Jun 30, 20264,0286
    2026Q1Mar 31, 20263,7208
    2025Q4Dec 31, 20254,8418
    2025Q3Sep 30, 20253,3577
    2025Q2Jun 30, 20254,6028
    2025Q1Mar 31, 20255,4038
    2024Q4Dec 31, 20245,4228

    2026Q3 Earnings Call

    Opening remarks

    Julie Dewey Chief IR and Communications Officer Thank you, and good morning, everyone. Welcome to Orthofix's third quarter 2026 earnings call. I'm Julie Dewey, Orthofix's Chief IR and Communications Officer. Joining me today are our President and Chief Executive Officer, Massimo Calafiore, and our Chief Financial Officer, Julie Andrews. Earlier today, Orthofix released financial results for the third quarter ended September 30, 2026. The press release and supplemental presentation are available on our Investor Relations website. A replay of this call will be posted shortly after we conclude. Before we begin, please note that our remarks include forward-looking statements. These statements involve risks and uncertainties, and actual results may differ materially. All statements other than those of historical fact are forward-looking statements. We do not undertake any obligation to revise or update such forward-looking statements, except as required by law. Factors that could cause actual results to differ materially are discussed in our most recent filings with the SEC and may be included in our future filings with the SEC. We will also reference certain non-GAAP financial measures during today's call, including certain growth rates presented on a pro forma constant currency basis and excluding discontinued M6 artificial disc product lines. Reconciliations to the most directly comparable U.S. GAAP measures and additional information are included in our press release and supplemental materials. Here's today's agenda. Massimo will begin with business performance and operational highlights. Julie Andrews will then review our financial results and guidance. After that, we'll open the call for questions. With that, I'll turn the call over to Massimo to discuss our third quarter performance. Massimo?

    Massimo Calafiore President and Chief Executive Officer Thank you, Julie, and good morning, everyone. I appreciate you joining us today. While third quarter results were below our expectation, we saw continued strength in limb reconstruction and Therapeutic Solutions and further stabilization in U.S. Biologics. In U.S. Spine, market softness and unplanned supplier delays created inventory and instrument set constraints. We have a clear recovery plan and are accelerating actions to improve execution and position the business for stronger performance. We are concentrating resources behind our strongest partners and the highest-value technology, simplifying the portfolio and aligning costs with a more focused business. These actions are intended to establish a stronger foundation for growth, profitability, and cash generation over time. To recap these actions in more detail, first, we are concentrating resources behind our strongest commercial partners. We are accelerating exits from nonstrategic, lower-performing relationships and redeploying instrument sets to faster-growing core distributors. These distributors now generate around 80% of U.S. spinal implant revenue, with a similar concentration among core products. We have already seen these strategies work in markets where we consolidated distribution around stronger partners.

    Frequently Asked Questions About OFIX

    When is Orthofix Medical's next earnings date?

    Orthofix Medical's next earnings report is expected for Feb 22, 2027.

    Did OFIX beat earnings estimates last quarter?

    Yes. Orthofix Medical reported EPS of -$0.15 for the quarter ended Sep 30, 2026, above the -$0.31 estimate, a 51.61% surprise.

    What EPS do analysts expect from OFIX next quarter?

    The consensus EPS estimate for Orthofix Medical for the quarter ending Dec 31, 2026 is -$0.07 from 4 analysts, with estimates from -$0.12 to -$0.02.

    How often does OFIX beat earnings estimates?

    Orthofix Medical beat the EPS estimate in each of the last 17 quarters, with an average surprise of +105.85%.